All In MedTech

Device Trial Radar · NCT02993211

Transurethral En Bloc Versus Standard Resection of Bladder Tumour

Transurethral En Bloc Versus Standard Resection of Bladder Tumour: A Multi-centre Randomised Controlled Trial (EB-StaR Study).

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Apr 18, 2017

Primary completion

Feb 11, 2022

Study completion Jun 9, 2022

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kwong Wah Hospital; North District Hospital; Our Lady of Maryknoll Hospital; Pok Oi Hospital; The University of Hong Kong; Tseung Kwan O Hospital, Hong Kong; Tuen Mun Hospital; Tung Wah Hospital; United Christian Hospital; Princess Margaret Hospital, Hong Kong; Caritas Medical Centre, Hong Kong; Queen Elizabeth Hospital, Hong Kong
First posted
Dec 15, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Conventionally, transurethral standard resection (SR) of bladder tumour is performed in a piecemeal manner. Transurethral en bloc resection (EBR) has been described as an alternate surgical technique in bladder tumour resection. By preventing tumour fragmentation and ascertaining complete tumour resection by histological assessment of the EBR specimen, we hypothesized that EBR could reduce disease recurrence as compared to SR.

Conditions

  • Bladder Cancer

Interventions

  • Bipolar transurethral standard resectionDevice

    Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)

  • Bipolar transurethral en bloc resectionDevice

    Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. One-year recurrence rateTime frame: One year after the allocated treatment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Caritas Medical Centre

    Hong Kong, Hong Kong

  • Kwong Wah Hospital

    Hong Kong, Hong Kong

  • North District Hospital

    Hong Kong, Hong Kong

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.